DDInter1588 DDInter1016
Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali.
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Mirabegron
Ribociclib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tadalafil
Ribociclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ripretinib
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Enzalutamide
Ribociclib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Mirabegron
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Tadalafil
Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Ribociclib may lead to a major life threatening interaction when taken with Enzalutamide
Ribociclib may lead to a major life threatening interaction when taken with Lurbinectedin